The market for pharmaceuticals is over.
News: there are two big events, first of all, Anhui out of the in vitro diagnostic products on the set of procurement documents, a July 14 held in Anhui Province, clinical test reagents business forum minutes circulated online, the record content, the clinical test reagents special bandwidth purchasing model is a bandwidth negotiation of the bargaining model, the initial selection of five categories of 23 products for product Centralized banded bargaining.
Another thing is that Hengrui Medicine's midterm report is less than expected, and the company released its midterm report for 2021. The company realized total operating income and attributable to shareholders of the parent company in the first half of 2021 were 13.298 billion yuan and 2.668 billion yuan, respectively, 17.58% and 0.21%. The first half of the performance quarter by quarter decline is mainly dragged down by the decline in sales of traditional generic drugs, and the impact will continue, the good thing is that the proportion of innovative drugs continue to increase, the company continues to promote research and development, the future with the gradual landing of the R & D pipeline, the proportion of generic drugs is expected to continue to reduce.
Interpretation: Review the last "4 + 7" band purchasing policy under the influence of the pharmaceutical sector trend appeared a "golden pit", the impact of the subsequent collection of medical equipment has a greater reference significance. Medical procurement is expected to become the norm. In the short term, although product prices may face a certain impact, but import substitution is still expected to bring price for volume dividends.